FDA indicates Nubeqa (darolutamide) to treat patients with non-metastatic castration-resistant prostate cancer. Bayer and Orion Corp. jointly developed the drug, which FDA approved in 2019. The approval came after FDA reviewed results from the Phase 3 ARAMIS study, which tested Nubeqa with androgen deprivation therapy (ADT) in patients with prostate cancer. The drug has continued to…